148 related articles for article (PubMed ID: 25302627)
1. Excess mortality among opioid-using patients treated with oral naltrexone in Australia.
Degenhardt L; Larney S; Kimber J; Farrell M; Hall W
Drug Alcohol Rev; 2015 Jan; 34(1):90-6. PubMed ID: 25302627
[TBL] [Abstract][Full Text] [Related]
2. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
Kelty E; Hulse G
Int J Drug Policy; 2017 Aug; 46():54-60. PubMed ID: 28609749
[TBL] [Abstract][Full Text] [Related]
3. Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.
Kelty E; Hulse G
Addiction; 2012 Oct; 107(10):1817-24. PubMed ID: 22487087
[TBL] [Abstract][Full Text] [Related]
4. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.
Gibson AE; Degenhardt LJ
Drug Alcohol Rev; 2007 Jul; 26(4):405-10. PubMed ID: 17564876
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
Kelty E; Hulse G
Drugs; 2017 Jul; 77(11):1199-1210. PubMed ID: 28536980
[TBL] [Abstract][Full Text] [Related]
6. Injectable extended-release naltrexone for opioid dependence.
Woody GE; Metzger DS
Lancet; 2011 Aug; 378(9792):664-5; author reply 666. PubMed ID: 21856476
[No Abstract] [Full Text] [Related]
7. Opioid-dependent error processing.
Fellows-Smith J
J Opioid Manag; 2011; 7(6):443-9. PubMed ID: 22320026
[TBL] [Abstract][Full Text] [Related]
8. Favorable mortality profile of naltrexone implants for opiate addiction.
Reece AS
J Addict Dis; 2010 Jan; 29(1):30-50. PubMed ID: 20390697
[TBL] [Abstract][Full Text] [Related]
9. Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality.
Kelty E; Hulse G; Joyce D; Preen DB
CNS Drugs; 2020 Jun; 34(6):629-642. PubMed ID: 32215842
[TBL] [Abstract][Full Text] [Related]
10. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
[TBL] [Abstract][Full Text] [Related]
11. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
[TBL] [Abstract][Full Text] [Related]
12. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
Tait RJ; Ngo HT; Hulse GK
J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
[TBL] [Abstract][Full Text] [Related]
13. Promise of extended-release naltrexone is a red herring.
Bart G
Lancet; 2011 Aug; 378(9792):663; author reply 663-4. PubMed ID: 21856474
[No Abstract] [Full Text] [Related]
14. A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.
Kelty E; Joyce D; Hulse G
Am J Drug Alcohol Abuse; 2019; 45(3):285-291. PubMed ID: 30848965
[TBL] [Abstract][Full Text] [Related]
15. [Documented effect of methadone, but not naltrexone].
Heilig M
Lakartidningen; 2002 Feb; 99(6):551-2. PubMed ID: 11881232
[No Abstract] [Full Text] [Related]
16. Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance.
Ngo HT; Tait RJ; Hulse GK
J Psychopharmacol; 2011 Jun; 25(6):774-82. PubMed ID: 20360157
[TBL] [Abstract][Full Text] [Related]
17. Course of weight change during naltrexone versus methadone maintenance for opioid-dependent patients.
Mysels DJ; Vosburg SK; Benga I; Levin FR; Sullivan MA
J Opioid Manag; 2011; 7(1):47-53. PubMed ID: 21434584
[TBL] [Abstract][Full Text] [Related]
18. A 'miracle cure' misunderstood.
Brewer C
Addiction; 2012 Aug; 107(8):1528. PubMed ID: 22594709
[No Abstract] [Full Text] [Related]
19. Clinical treatment of opioid addiction and dependence.
Ling W; Rawson RA; Compton M
Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
[No Abstract] [Full Text] [Related]
20. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
Winstock AR; Lea T; Sheridan J
Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
